Question 1

How much time will our pharma RA team actually save?

Accepted Answer

Teams using Assyro draft regulatory documents 14x faster and cut validation time by 50%. On a typical NDA cycle, that translates to 100+ recovered hours and $150-250K in avoided rework, contractor fees, and delayed revenue.

Question 2

Can Assyro handle NDA, sNDA, BLA, and IND submissions?

Accepted Answer

Yes. Assyro supports all major FDA submission types with pre-configured workflows for each. The same execution system handles original applications, supplements, amendments, and annual reports.

Question 3

How does Assyro catch eCTD defects before submission?

Accepted Answer

Assyro validates your eCTD sequences against FDA gateway technical specs in real time as your team works. Structural, lifecycle, and metadata defects are flagged with specific fix instructions before dispatch.

Question 4

We already have a publishing tool. Why switch?

Accepted Answer

Most publishing tools validate after the fact. Assyro validates continuously during the drafting and review process, so defects never reach your publishing step. It works alongside your existing stack, not instead of it.

Question 5

Why is Assyro a fit for Pharma organizations?

Accepted Answer

Pharma organizations usually need to coordinate multiple owners, deadlines, and evidence streams without letting execution quality slip. Assyro helps teams cut nda and snda prep time by 60% with ai-assisted drafting and automated readiness checks while keeping readiness, status, and traceability in one system.

Question 6

Can Assyro support multiple programs, sponsors, or clients for Pharma teams?

Accepted Answer

Yes. Shared workflow controls work well in environments where multiple programs move in parallel and leaders need one clear view of status, risk, and ownership. Teams keep program-level traceability without rebuilding the process for each client or sponsor.

Question 7

How does Assyro work with the systems Pharma teams already use?

Accepted Answer

Assyro does not require you to rip out every existing system. It gives Pharma teams a better execution layer around current documents, reviews, and validation checkpoints so the operating model becomes more consistent without a full rebuild.

Question 8

How does Assyro reduce rework for Pharma teams?

Accepted Answer

Assyro reduces rework by keeping tasks, evidence, approvals, and validation context connected from the start. That makes it easier for Pharma teams to validate ectd sequences in real time against fda technical specs before gateway dispatch before the filing window gets tight.

Pharma Regulatory Submission Software

Pharma Submission Workflow

Go From 3 Weeks of Review Cycles to 48 Hours

Stop Losing Documents Between 5 Different Systems

Know Your Exact Readiness Score at Any Moment

Never Miss a Submission Deadline Again

Pharma Workflow Controls at Scale

Maintain Audit-Ready Submission Workflows

Manage More Pharma Programs With the Same Team Size

Questions About Pharma Workflows

See Pharma Submission Workflows in Assyro.